

Kazem Nasserinejad

Curriculum Vitae

Oct. 2021. Rotterdam
✉ info@consultistics.nl
<https://www.consultistics.nl/>

Academic Education

- 2011–2016 **Ph.D. in Biostatistics**, *Department of Biostatistics*, Erasmus MC, Rotterdam.
2008–2011 **M.Sc. in Biostatistics**, *Department of Biostatistics*, Beheshti University, Tehran.
2003–2007 **B.Sc. in Statistics**, *Department of Statistics*, Beheshti University, Tehran.

Work Experience

- 2019 – Present **Statistician, Department of Hematology, Erasmus MC, Rotterdam.**
Main focus on writing of protocols and statistical analysis plans, performing statistical analysis, writing reports, and scientific papers in HOVON studies (<http://www.hovon.nl/>).
- 2019 – 2019 **Assistant professor, Department of Hematology, Amsterdam UMC, Amsterdam.**
Main focus on statistical consultancy, preparing statistical analysis plans, performing data analysis, participating in the writing of protocols, reports, and scientific papers.
- 2016 – 2018 **Statistician, Department of Hematology, Erasmus MC, Rotterdam.**
Main focus on writing of protocols and statistical analysis plans, performing statistical analysis, writing reports, and scientific papers in HOVON studies (<http://www.hovon.nl/>).
- 2011 – 2016 **PhD Candidate and researcher, Department of Biostatistics, Erasmus MC.**
Main focus on developing Bayesian statistical techniques for predicting and modeling longitudinal data of blood donors, statistical consultant, and teacher assistant in (Bayesian) statistical courses provided by NIHES in Erasmus MC.
- 2008 – 2011 **Statistical consultant, Tehran.**
Statistician and researcher at research company *Business excellent Consultants Group*.
- 2005 – 2007 **Statistical consultant, Tehran.**
Statistician and researcher at research company *Customer Oriented Management Consultant*.

Statistical advisor

- 2015 – Present **Developmental Medicine and Child Neurology Journal.**
2020 – Present **Educational and Psychological Measure Journal .**

Ph.D Students

- 2017 **Committee member of Ph.D thesis**, "*Joint Modeling for Longitudinal and Time-to-Event data with Applications in Health Insurance*", Xavier Piulachs Lozada-Benavente, Faculty of Economy and Business, University of Barcelona, Barcelona, Spain.
- 2021 **Co-promotor of Ph.D student**, *Claudia Stege*, Dep. of Hematology, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands.

Awards

- 2015 – 2015 **15th CEB - EIB conference, Bilbao, Spain (Student award).**

Research interests

- (Bayesian) Meta-analysis

- (Bayesian) Longitudinal and mixed-effects model
- Randomized Controlled Clinical Trials
- (Bayesian) Mixture models
- (Bayesian) Programming and statistical computing
- Big (high dimensional) data

Publication

- Kersten, M.J, Amaador, K, Minnema, M.C, Vos, J.M, Nasserinejad K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M.E.D, Deeren, D, Tick, L.W, Doorduijn, J.K, Offner F, Böhmer, L.H, Liu, R.D, Pals, S.T, Dimopoulos, M.A. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. *Journal of Clinical Oncology*, 2021.
- Stege, C.A, Nasserinejad K, van der Spek, E, Bilgin, Y.M, Kentos, A, Sohne, M, van Kampen, R.J.W, Ludwig, I, Thielen, N, Durdu-Rayman, N, de Graauw, N.C.H.P, van de Donk, N.W.C.J, de Waal, E.G.M, Vekemans, M-C, Timmers, G-J, van der Klift, M, Soechit, S, Geerts, P.A.F, Silbermann, M.H, Oosterveld, M, I.S. Nijhof, Sonneveld, P, Klein, S.K, Levin, M-D, Zweegman, S. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. *Journal of Clinical Oncology*, 2021.
- Stege, C.A, Nasserinejad K, Klein, S.K, Timmers, G.J, Hoogendoorn, M, Ypma, P.F, Nijhof, I.S, Velders, G.A, Strobbe, L, Durdu-Rayman, N, Westerman, M, Davidis-van Schoonhoven, M.A, van Kampen, R.J.W, Beeker, A, Koster, A, Dijk, A.C, van de Donk, N.W.C.J, van der Spek, E, Leys, R.B.L, Silbermann, M.H, Groen, K, van der Burg-de Graauw, N.C.H.P., Sinnige, H.A.M, van der Hem, K.G, Levenga, H, Bilgin, Y.M, Sonneveld, P, Levin, M-D, Zweegman, S. Improving the identification of frail elderly newly diagnosed multiple myeloma patients. *Leukemia*, 2021.
- Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink C, Dobber JA, Poulsen CB, Frederiksen H, Janssens AM, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Kater A. Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. *Blood*, 2020.
- Bos MK, Nasserinejad K, Jansen MP, Angus L, Atmodimedjo PN, de Jonge E, Dinjens WNM, van Schaik RHN, Del Re M, Dubbink HJ, Sleijfer S, Martens JWM. Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. *Molecular Oncology*, 2020.
- Svanberg R, Ostrowski SR, Nasserinejad K, Kersting S, Dobber JA, Mattson M, Tran HTT, Levin MD, Mous R, Kater AP, Niemann CU. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. *Leukemia & Lymphoma*, 2020.
- Kloosterboer SM, de Winter BC, Reichart CG, Kouijzer ME, de Kroon MM, van Daalen E, Ester WA, Rieken R, Dieleman GC, van Altena D, Bartelds B, van Schaik RHN, Nasserinejad K, Hillegers MHJ, van Gelder T, Dierckx B, Koch BCP. Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. *British Journal of Clinical Pharmacology*, 2020.
- Levin, M. D., Kater, A., Mattsson, M., Kersting, S., Ranti, J., Tran, H. T. T., Nasserinejad K, Niemann, C. U. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. *BMJ open*, 2020.
- Andrinopoulou E, Nasserinejad K, Szczesniak R, Rizopoulos D. Integrating Latent Classes in the Bayesian Shared Parameter Joint Model of Longitudinal and Survival Outcomes. *Statistical Methods in Medical Research*,

2020.

- Busse A. M, Hoeve H. L, Nasserinejad K, Mackey A. R, Simonsz H. J, Goedegebure A. Prevalence of permanent neonatal hearing impairment: systematic review and Bayesian meta-analysis. *International Journal of Audiology*, 1-11. 2020
- Bos M. K, Angus L, Nasserinejad K, Jager A, Jansen M. P, Martens J. W, Sleijfer S. Whole exome sequencing of cell-free DNA—a systematic review and Bayesian individual patient data meta-analysis. *Cancer Treatment Reviews*, 101951. 2019
- Minnema M. C, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma P. F, ... , Croockewit S. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. *haematologica*, 104(11), 2274-2282. 2019
- Eijgenraam S. M, Bovendeert F. A, Verschueren J, van Tiel J, Bastiaansen-Jenniskens Y. M, Wesdorp M. A, Nasserinejad K, Meuffels DE, Guenoun J, Klein S, Reijman M, Oei EHG. T 2 mapping of the meniscus is a biomarker for early osteoarthritis. *European radiology*, 29(10), 5664-5672. 2019
- Croles F.N., Borjas-Howard J, Nasserinejad K, Leebeek F.W.G, Meijer K. Risk of venous thrombosis in antithrombin deficiency: A systematic review and Bayesian meta-analysis. *Seminars in Thrombosis and Hemostasis Journal*. 2017.
- Croles F.N., Nasserinejad K, Duvekot J.J, Kruip M.J.H.A, Meijer K, Leebeek F.W.G. Pregnancy, thrombophilia and the risk of a first venous thrombosis: A systematic review and Bayesian meta-analysis. *British Medical Journal*. 2017.
- Hywood J, Teixeira-Pinto A, Nasserinejad K, McCusker E, Loy C. Predicting individual disease progression in huntington's disease using mixed models and transition models. *Journal of Neurology Neurosurgery and Psychiatry*. 2017.
- Kuo W, de Bruijne M, Petersen J, Nasserinejad K, Ozturk H, Chen Y, Perez-Rovira A, A.W.M. Tiddens H. Diagnosis of bronchiectasis in children with cystic fibrosis: Objective airway-artery quantification. *European Radiology*. 2017.
- Nasserinejad K, van Rosmalen J, de Kort W, Lesaffre E. Comparison of criteria for choosing the number of classes in Bayesian finite mixture models. *PLOS ONE*. 2017.
- van den Heuvel D, Jansen MAE, Nasserinejad K, DikWA, van Lochem EG, Bakker-Jonges LE, Bouallouch-Charif H, Jaddoe VVW, Hooijkaas H, van Dongen JJM, Moll HA, van Zelm MC. Effects of external determinants on age-related patterns of innate leukocyte and naive and memory B- and T-lymphocyte numbers in early childhood: The generation R-study. *The Journal of Allergy and Clinical Immunology*. 2016.
- van Lee CB, Ip Vai Ching EE, Nasserinejad K, Neumann HA, Bol MG, Dikrama PK, Kelleners-Smeets NW, Koljenovi ć S, Munte K, Noordhoek Hegt V, de Vijlder HC, Nijsten T, van den Bos RR. Reliability of Mohs slides diagnosis: interpersonal and intrapersonal agreement on basal cell carcinoma presence and histological subtype. *British Journal of Dermatology*. 2016.
- Stipdonk LW, Weisglas-Kuperus N, Franken MC, Nasserinejad K, Dudink J, Goedegebure A. Auditory brainstem maturation in normal-hearing preterm infants: A meta-analysis. *Developmental Medicine and Child Neurology*. 2016.
- Nasserinejad K, van Rosmalen J, de Kort W, Rizopoulos D, Lesaffre E. Prediction of hemoglobin in blood donors using a latent class mixed-effects transition model. *Statistics in Medicine*. 2016 ;35(4):581-94.
- van Tiel J, Siebelt M, Reijman M, Bos PK, Waarsing JH, Zuurmond AM, Nasserinejad K, van Osch GJ, Verhaar JA, Krestin GP, Weinans H, Oei EH. Quantitative in vivo CT arthrography of the human osteoarthritic

knee to estimate cartilage sulphated glycosaminoglycan content: correlation with ex-vivo reference standards. *Osteoarthritis and Cartilage*. 2016.

- van Tiel J, Kotek G, Reijman M, Bos PK, E. Bron EE, Klein S, Nasserinejad K, van Osch GJ, Verhaar JA, Krestin GP, Weinans H, Oei EH. Is T1rho-mapping an alternative to delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) in assessing sulphated glycosaminoglycan content in human osteoarthritic knees? An in vivo validation study. *Radiology*. 2015.
- van Lee CB, Graafland B, Koljenovi ć S, Neumann HA, Nasserinejad K, Nijsten TE, van den Bos RR, Munte K. Additional review of Mohs slides to optimize Mohs micrographic surgery. *British Journal of Dermatology*. 2015; 173(1):123-7.
- Nasserinejad K, van Rosmalen J, van den Hurk K, Baart M, Hoekstra T, Rizopoulos D, Lesaffre E, de Kort W. Prevalence and determinants of declining versus stable hemoglobin levels in whole blood donors. *Transfusion*. 2015; 55(8):1955-63.
- Camfferman FA, Ecury-Goossen GM, La Roche JE, de Jong N, van't Leven W, Vos HJ, Verweij MD, Nasserinejad K, Cools F, Govaert P, Dudink J. Calibrating Doppler imaging of preterm intracerebral circulation using a microvessel flow phantom. *Frontiers in Human Neuroscience*. 2013.
- Runia TF, van Meurs M, Nasserinejad K, Hintzen RQ. No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis. *Multiple Sclerosis Journal*. 2014 31:1352458514528765.
- Nasserinejad K, de Kort W, Baart M, Komarek A, van Rosmalen J, Lesaffre E. Predicting hemoglobin levels in whole blood donors using transition models and mixed effects models. *BMC Medical Research Methodology*. 2013;13(1):62.